Bio­haven adds near­ly $1B in Nurtec deals with Roy­al­ty Phar­ma, Sixth Street

Bio­haven just added near­ly $1 bil­lion to their bal­ance sheet.

On Fri­day morn­ing, the neu­ro­science biotech an­nounced a pair of cre­ative agree­ments with Roy­al­ty Phar­ma and the in­vest­ment firm Sixth Street to bol­ster the com­mer­cial launch of their new mi­graine drug, Nurtec. Bio­haven will sell a sliv­er of its roy­al­ties on Nurtec and 3% of the roy­al­ties on their ex­per­i­men­tal mi­graine drug za­veg­epant to Roy­al­ty Phar­ma as part of a larg­er agreee­ment that will pay $450 mil­lion. At the same time, the com­pa­ny an­nounced they took out a $500 mil­lion loan from Sixth Street.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER